Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM-RAFT is an oral antacid combination syrup marketed by Cam Neuro Pharma for the symptomatic relief of heartburn, dyspepsia, and gastroesophageal reflux disease (GERD). As an antacid combination, it primarily works by neutralizing excess gastric acid in the stomach, thereby increasing the pH of gastric contents and reducing the irritation of the esophageal and gastric mucosa. The name 'RAFT' typically suggests a raft-forming mechanism, a common feature in similar antacid formulations where an alginate component reacts with gastric acid to form a neutral-pH physical barrier (a 'raft') that floats on top of the stomach contents. This barrier physically prevents the reflux of acidic gastric juice into the esophagus, providing rapid and sustained relief from symptoms of acid reflux.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAM-RAFT.